Home > Healthcare > Pharmaceuticals > Finished Drug Form > Carbapenem Market
Carbapenem Market size was valued at around USD 4 billion in 2023 and is estimated to grow at 5% CAGR from 2024 to 2032. Carbapenems are a class of highly effective antibiotics used to treat severe or high-risk bacterial infections.
They belong to the beta-lactam family of antibiotics, which work by inhibiting the synthesis of the bacterial cell wall, ultimately leading to the death of the bacteria. Carbapenems are considered broad-spectrum antibiotics because they are effective against a wide variety of gram-positive and gram-negative bacteria, including many strains that are resistant to other antibiotics.
Report Attribute | Details |
---|---|
Base Year: | 2023 |
Carbapenem Market Size in 2023: | USD 4 Billion |
Forecast Period: | 2024 - 2032 |
Forecast Period 2024 - 2032 CAGR: | 5% |
2032 Value Projection: | USD 6.2 Billion |
Historical Data for: | 2021 - 2023 |
No. of Pages: | 167 |
Tables, Charts & Figures: | 184 |
Segments covered: | Drug Class, Application, Distribution Channel, and Region |
Growth Drivers: |
|
Pitfalls & Challenges: |
|
The rising incidence of antimicrobial resistance is a significant driver for the market. For instance, according to the World Health Organization (WHO), antimicrobial resistance (AMR) is one of the foremost global public health and development threats. In 2019, it is estimated that bacterial AMR directly caused 1.27 million deaths worldwide and contributed to a total of 4.95 million deaths. Therefore, this underscores the urgent need for new and effective antimicrobial agents, driving innovation and investment in the development of novel antibiotics and alternative treatments to combat resistant bacterial infections.
Furthermore, high R&D investments in clinical research, growing incidence of hospital-acquired infections, and increased awareness and diagnostic advancements, are driving factors for the market growth.